Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis Source: Eur Respir J 2016; 48: 1612-1621 Year: 2016
Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020
The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006
Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014
The effectiveness of pulmonary rehabilitation in interstitial lung diseases in terms of functional markers Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018
Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020
Elucidating progression of early cystic fibrosis lung disease Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017 Year: 2017
Monitoring early lung disease in cystic fibrosis: where are we now? Source: Breathe 2014; 10: 34-47 Year: 2014
Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019
Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series Source: Eur Respir J 2006; 28: Suppl. 50, 263s Year: 2006
Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002
Do causes influence clinical, functional and quality of life aspects on patients with bronchiectasis not associated with cystic fibrosis? Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions Year: 2019
The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018 Year: 2019
Treatment of advanced cystic fibrosis lung disease and end of life decisions Source: School Course 2013 - Cystic Fibrosis Year: 2013
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021
Relations between the sinonasal development and the lung disease in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 103s Year: 2005
Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort Source: Eur Respir J, 55 (4) 1901694; 10.1183/13993003.01694-2019 Year: 2020
Improving airway clearance in cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 169-187 Year: 2014